A Food and Drug Administration advisory panel on Tuesday declined to recommend the approval of MDMA, commonly known as ecstasy or molly, as a treatment for post-traumatic stress disorder, a major setback for advocates who have long pushed to include psychedelics in treating mental health disorders. NBC News Health
A Food and Drug Administration advisory panel on Tuesday declined to recommend the approval of MDMA, commonly known as ecstasy or molly, as a treatment for post-traumatic stress disorder, a major setback for advocates who have long pushed to include psychedelics in treating mental health disorders.
